Immuno-Oncology Translation Network: Data Management and Resource-Sharing Center at RPCI

免疫肿瘤学翻译网络：RPCI 的数据管理和资源共享中心

• 批准号: 10175624
• 负责人: Alan David Hutson
• 金额: $ 84.1万
• 依托单位: ROSWELL PARK CANCER INSTITUTE CORP
• 依托单位国家: 美国
• 财政年份: 2018
• 资助国家: 美国
• 起止时间: 2018-09-30 至 2023-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10175624
• 关键词: Address; Atlas of Cancer Mortality in the United States; Awareness; Bioconductor; Bioinformatics; Biometry; Biostatistics Shared Resource; Buffaloes; Cancer Center Support Grant; Catalogs; Clinical; Collaborations; Combined Modality Therapy; Communication; Communities; Comprehension; Comprehensive Cancer Center; Computer software; Computing Methodologies; Data; Data Analyses; Data Analytics; Data Management Resources; Databases; Dependence; Development; Drug Kinetics; Drug resistance; Education and Outreach; Ensure; Fostering; Funding; Goals; Hand; Immunooncology; Immunotherapy; Informatics; Information Technology; Infrastructure; Intranet; Logistics; Malignant Neoplasms; Manuscripts; Methods; Multiomic Data; Oncology; Performance; Policies; Positioning Attribute; Preparation; Principal Investigator; Procedures; Productivity; PubMed; Records; Reproducibility; Research; Research Design; Research Personnel; Research Project Grants; Resistance; Resource Sharing; Resources; Structure; Supercomputing; System; Text; Training and Education; Translations; United States National Institutes of Health; Universities; anti-cancer therapeutic; biobank; bioinformatics tool; cancer therapy; combat; data harmonization; data integration; data management; data repository; data sharing; data tools; design; drug sensitivity; expectation; experience; high standard; improved; innovation; interest; member; metabolomics; multidisciplinary; multiple omics; open source; operation; outreach; predictive marker; protocol development; quality assurance; real time monitoring; resistance mechanism; response; social media; support network; translational study; tumor; web portal

This application is being submitted in response to the Notice of Special Interest (NOSI) identified as NOT-CA- 20-052. Project Summary While several innovative and creative anti-cancer therapies have shown promising results, a significant expansion of their clinical use will require collaborative efforts to elucidate resistance mechanisms, exploit tumor sensitivity, map cancer dependence, discover new targets, identify predictive biomarkers, evaluate combination therapies, and develop real-time monitoring approaches. Leveraging cutting-edge multi-disciplinary team approaches, we will support the NCI Drug Resistance and Sensitivity Network (DRSN) to understand and combat mechanisms of tumor resistance and to exploit tumor sensitivity to anti-cancer therapies. Our strategy is to serve as an administration, communication, collaboration and analysis hub to coordinate the DRSN’s network-wide studies, focusing on reducing barriers to domain expertise, improving the productivity of DRSN investigators, maintaining a high standard for data harmonization and integration, designing and implementing rigorous analytical strategies, and fostering a collaborative and supportive research community. An experienced, multidisciplinary team has been assembled to pursue five Specific Aims: First, we will provide a centralized administration infrastructure to coordinate DRSN activities, building upon the Immuno-Oncology Translational Network (IOTN) Data Management and Resource-sharing Center (DMRC)’s well-functioning infrastructure that currently coordinates network studies under the umbrella of the NCI Cancer Moonshot initiative. Second, we will actively promote the DRSN and foster trans-consortium interactions, where we will leverage the IOTN DMRC’s demonstrable experience in Cross-Moonshot outreach and Bioconductor’s decades-long record in community-wide engagement. Third, we will provide multidisciplinary expertise to support DRSN collaborative research, leveraging four of the Roswell Park CCSG’s shared resources: Biostatistics, Bioinformatics, Data Bank and BioRepository, Bioanalytics, Metabolomics & Pharmacokinetics. Our analytic support will be armed with professional IT staff and informed by an experienced anti-cancer therapeutic researcher team. Fourth, we will develop innovative multi-omics data integration methods to enhance DRSN’s research capacity, capitalizing on the well-respected and highly-successful Bioconductor project. Fifth, we will disseminate resources developed in the DRSN to the broader community, unleashing the full potential of DRSN activities. Taken together, we envision our CC, in close collaboration with the DRSN components, will allow us to conduct highly effective and innovative translational studies to address the significantly unmet needs related to anti-cancer therapeutics, and fulfill the expectations and guiding principles of NCI Cancer Moonshot initiative.

本申请是为了响应被识别为 NOT-CA- 的特殊利益通知 (NOSI) 而提交的 20-052。 项目概要 虽然一些创新和创造性的抗癌疗法已显示出有希望的结果，但 扩大其临床用途将需要共同努力来阐明耐药机制、利用肿瘤 敏感性、绘制癌症依赖性、发现新靶标、识别预测生物​​标志物、评估组合 疗法，并利用尖端的多学科团队开发实时监测方法。 方法，我们将支持 NCI 耐药性和敏感性网络 (DRSN)，以了解和应对 我们的策略是服务于肿瘤耐药机制并利用肿瘤对抗癌疗法的敏感性。 作为管理、通信、协作和分析中心，协调 DRSN 的网络范围 研究，重点是减少领域专业知识的障碍，提高 DRSN 研究人员的生产力， 保持数据协调和集成的高标准，设计和实施严格的 分析策略，并培养协作和支持性的研究社区。 我们组建了一支经验丰富的多学科团队来追求五个具体目标：首先，我们将提供 以免疫肿瘤学为基础，协调 DRSN 活动的集中管理基础设施 翻译网络（IOTN）数据管理和资源共享中心（DMRC）运作良好 目前在 NCI 癌症登月计划的框架下协调网络研究的基础设施 其次，我们将积极推动 DRSN 并促进跨联盟互动。 利用 IOTN DMRC 在 Cross-Moonshot 推广和 Bioconductor 方面的丰富经验 第三，我们将提供跨学科的专业知识。 利用罗斯威尔公园 CCSG 的四个共享资源支持 DRSN 协作研究： 生物统计学、生物信息学、数据库和生物资源库、生物分析、代谢组学和药代动力学。 分析支持将配备专业的 IT 人员，并由经验丰富的抗癌治疗师提供信息 第四，我们将开发创新的多组学数据集成方法来增强 DRSN 的能力。 第五，我们将利用备受推崇且非常成功的 Bioconductor 项目。 将 DRSN 开发的资源传播给更广泛的社区，释放 DRSN 的全部潜力 总而言之，我们预计我们的 CC 与 DRSN 组件密切合作，将使我们能够实现这一目标。 进行高效和创新的转化研究，以解决相关的严重未满足的需求 抗癌治疗，并实现 NCI 癌症登月计划的期望和指导原则。